Skin News and Research

RSS

HAE patients have prodromal symptoms that signal an oncoming HAE attack, reports survey

Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.

9 Nov 2009

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009

Eggs sensitivity and flu shot: Doctors' dilemma

"My three year old had a skin breakout we think was due to eggs - is it safe to do a flu shot?" It's a question being asked to every doctor who takes care of kids during flu season. "On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we aren't sure if a history of eggs sensitivity is enough to hold the shot or spray," said Bobby Q. Lanier, M.D., clinical professor of pediatrics at the University of North Texas HSC in Fort Worth, Texas, and executive medical director of the American College of Allergy, Asthma and Immunology (ACAAI).

6 Nov 2009

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

6 Nov 2009

Incontinence has a significant impact on caregiver's life

Incontinence in a parent, grandparent or spouse has a significant emotional impact on a caregiver's life, according to a survey released today by Caring.com and SCA, the makers of TENA® (www.tena.us).

6 Nov 2009

New breast reconstruction surgery for women

Since her teens, Jennifer Jablon had watched family members deal with breast cancer during their 40s, 50s, and 60s. She wondered whether it would be her fate too.

6 Nov 2009

Non-invasive "optical biopsy" to detect breast cancer

Most biopsies following mammograms reveal benign abnormalities, not cancer.

6 Nov 2009

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

SAVI 6-1Mini applicator is the only brachytherapy solution for patients with small breasts, says study

The SAVI™ 6-1Mini breast brachytherapy applicator is the only brachytherapy solution for patients with small breasts, hard-to-reach lumpectomy cavities, or cavities close to the skin surface, according to a new study.

6 Nov 2009

$1.85 million grant to study how digital games can improve players' health behaviors and outcomes

The Robert Wood Johnson Foundation (RWJF) today announced more than $1.85 million in grants for research that will offer unprecedented insight into how digital games can improve players' health behaviors and outcomes. With funding from RWJF's Health Games Research national program, nine research teams across the country will conduct extensive studies to discover, for example, how the popular dance pad video game Dance Dance Revolution might help Parkinson's patients reduce the risk of falling, how Wii Active might be most effectively implemented in high schools to help overweight students lose weight, how a mobile phone game with a breath interface might help smokers quit or reduce their tobacco use, or how facial recognition games might be designed to help people with autism learn to identify others' emotions.

From Evident Corporation - Life Sciences 6 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

Dietary options and better detection improve food allergy management procedures

Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

5 Nov 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Pennsaid Topical Solution approved by FDA

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid® Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Plant carotenoids are the most important source of vitamin A in the human diet

Carotenoids-fat-soluble plant compounds found in some vegetables-are essential to the human diet and reportedly offer important health benefits to consumers. Plant carotenoids are the most important source of vitamin A in the human diet; the carotenoids lutein and zeaxanthin, found in corn and leafy greens vegetable such as kale, broccoli, and spinach, are widely considered to be valuable antioxidants capable of protecting humans from chronic diseases including age-related macular degeneration, cancer, and cardiovascular disease.

5 Nov 2009

Scientists identify a novel cellular source of atrial fibrillation

While studying how the heart is formed, scientists at the University of Pennsylvania School of Medicine serendipitously found a novel cellular source of atrial fibrillation (AF), the most common type of abnormal heart beat.

5 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Department of Health urges healthcare professionals to be vaccinated against H1N1 flu

Saying healthcare workers are "on the front lines" of battling the H1N1 flu pandemic, the Department of Health today urged healthcare professionals across Pennsylvania to be vaccinated against the H1N1 flu.

4 Nov 2009